The position of SGLT2 inhibitors in current medical practice - update 2022
{{output}}
Cardiovascular diseases are still the most common cause of mortality in patients with type 2 diabetes. Studies on the cardiovascular safety of new antidiabetic treatments, that have significantly expanded the treatment options for type 2 diabetes over the last... ...
